MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today presents the results of its Annual and Extraordinary General Meeting held on Friday, June 20, 2025 at 9:30 am CET at the Company's office and broadcasted live (replay available here). The quorum reached by the shareholders present, representing, or voting remotely, was above 73% of voting shares.
Shareholders overwhelmingly approved most of the resolutions put forward by the Board of Directors by a majority of over 99% (with the exception of the 29th and 34th resolutions approved by nearly 69% of voters). The following resolutions were approved:
Approval of the financial statements for fiscal year 2024;
The compensation policy for corporate officers (Chairman, Chief Executive Officer and Directors) and the compensation paid or awarded during 2024 fiscal year – details of the votes on the said resolution is available on the Company's website here;
Financial resolutions, notably delegations of authority to the Board of Directors to carry out capital increases in various situations;
Delegation of authority to the Board of Directors to decide on any merger, demerger or partial contribution of assets (29th resolution).
Only one resolution was rejected:
Delegation of authority to the Board of Directors to carry out a capital increase through the issue of shares or securities giving access to the capital, reserved for members of a company savings plan, with the cancellation of preferential subscription rights in their favor (36th resolution).
Shareholders also approved the renewal of the terms of office for current directors Mr. Jean-Marie Lefèvre, Mrs. Dorothée Burkel, Mrs. Nadia Kamal, Mr. Claude Bertrand, Mr. Hervé Affagard, Mr. Jean Volatier, Seventure Partners, and the appointment of a representative from Bpifrance Investissement as a director. It is also noted that the presidency of Mr. Karim Dabbagh came to an end at the close of the Annual Shareholders' Meeting on June 20, 2025, as his mandate is reaching its term. The Board and the Company thank Mr. Dabbagh for his contribution and his service as Chairman and wishes him every success in his future endeavors. Following the Annual General Meeting, the Board of Directors meeting that took place on June 24 th, 2025, appointed Mr. Jean-Marie Lefèvre as Chairman of the Board for the duration of his term of office, which he had previously led for 5 years between 2018-2023.
In accordance with the approval of resolutions 19 and 20, the Company also announces that the Board of Directors has decided to maintain the liquidity contract signed with Kepler Cheuvreux for the liquidity of the Company's shares listed on Euronext Paris. Information on this contract is available in the Company's Universal Registration Document (French only).
The full minutes of the Annual General Meeting and the results of the votes, resolution by resolution, will be made available shortly on the Company's website www.maatpharma.com in the Investors/Shareholder Meetings' section.
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
Symetra Named to 2025 PEOPLE ® Companies That Care™ List
BELLEVUE, Wash.--(BUSINESS WIRE)--Symetra Life Insurance Company, a national provider of life, retirement and employee benefits insurance products, announced that it has been named to the 2025 PEOPLE ® Companies That Care List ™, coming in at No. 71 among the top 100 organizations recognized. Compiled by Great Place To Work ® and PEOPLE magazine, the annual list honors companies that 'go the extra mile to honor their customers, empower their employees, and make the world a better place.' 'Serving our customers, supporting our employees, and innovating for the future are critically important to our long-term success, but equally vital is our work to support and give back to our communities." — Symetra CEO Margaret Meister Share 'Witnessing the innovative spirit with which these companies invest in their employees, communities, and the world is truly invigorating," says Charlotte Triggs, PEOPLE GM and editor-in-chief. 'Their commitment reflects our mission, to feature what happens when ordinary people do extraordinary work.' The Companies That Care List is based on over 1.3 million employee survey responses and data from Great Place To Work Certified™ companies representing the experience of more than 8.4 million employees. More than a million surveys came from employees at companies eligible for this year's list, and these rankings are based on that feedback. When surveyed, 92 percent of Symetra's employees said the company is a great place to work, and 95 percent of those surveyed said they felt good about the ways Symetra contributed to the community. 'Symetra is incredibly proud to be recognized by PEOPLE and Great Place to Work and included among the organizations whose culture reflects a commitment to community,' said Margaret Meister, president and CEO, Symetra Financial Corp. 'Serving our customers, supporting our employees, and innovating for the future are critically important to our long-term success, but equally vital is our work to support and give back to our communities. Through our corporate social responsibility program, Symetra Social Impact, we aim to be intentional and transparent about the goals we've set and the progress we're making to create positive impact for people and for the planet alongside our community partners.' 'Businesses are vital pillars in the communities where they operate,' says Michael C. Bush, CEO of Great Place To Work. 'Caring for your people and your community isn't something you do after you build a successful business; it's how to make your business successful.' The Companies That Care ranking is among multiple recognitions Symetra has recently earned. In May, the company was named to the Puget Sound Business Journal's Corporate Philanthropists list in the large company category for the fifth consecutive year. In 2024, Symetra was again recognized as a Fortune Best Workplaces for Women™ and a Fortune Best Workplaces in Financial Services & Insurance™ and also earned Fortune Best Workplaces for Parents™ and Fortune Best Workplaces for Millennials™ honors. To learn more about Symetra Social Impact and how we support our employees' volunteerism and giving efforts, visit About Symetra Symetra Life Insurance Company is a subsidiary of Symetra Financial Corporation, a diversified financial services company based in Bellevue, Washington. In business since 1957, Symetra provides employee benefits, annuities and life insurance through a national network of benefit consultants, financial institutions, and independent financial professionals and insurance producers. For more information, visit About Great Place To Work As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified and receiving recognition on a coveted Best Workplaces™ List. About the PEOPLE Companies That Care List Great Place To Work selected the 2025 PEOPLE Companies That Care List by gathering and analyzing over 1.3 million confidential survey responses from companies representing more than 8.4 million U.S. employees at Great Place To Work Certified organizations. Of those, more than a million responses came from employees at companies eligible for the list and these rankings are based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index™ Survey. PEOPLE's Companies That Care Logo® is a registered trademark of TI Gotham, Inc., a Dotdash Meredith company. Used under license.
Business Wire
31 minutes ago
- Business Wire
Camunda Recognized for 'Best-in-Class Orchestration' in Digital Process Automation Software 2025 Report
SAN FRANCISCO--(BUSINESS WIRE)-- Camunda, the leader in process orchestration and automation, has been named as a Strong Performer in The Forrester Wave™: Digital Process Automation Software, Q3 2025. According to the report, '(Camunda's) focus on endpoint orchestration provides a strong foundation for its excellent vision and innovation, which includes a unique approach to agentic orchestration based on BPMN.' This comes at a time when unclear ROI, weak data foundations, and a lack of in-house expertise risk stalling many AI initiatives. 'We're proud to be recognized as a Strong Performer in the latest Forrester Wave™ Digital Process Automation report,' said Daniel Meyer, CTO, Camunda. 'Agentic AI is opening up new possibilities for business process automation. But without orchestration, AI agents lack the coordination, accountability, and reliability needed for real-world, business-critical processes. Camunda's agentic orchestration is the fastest route from AI pilot to production-scale ROI without sacrificing transparency or governance.' Camunda received the highest possible score in the following criteria: Orchestration that unifies multiple adjacent and complementary endpoint automations that cross application and infrastructure boundaries. Support for process standards such as Business Process Model and Notation (BPMN), Decision Model and Notation (DMN), and Model Context Protocol (MCP). The report states that Camunda's cloud-native workflow engine, Zeebe, 'earns top marks for orchestration with a distributed and stateful approach' that enables high-performance, resilient process execution. In addition, Camunda's support for BPMN, DMN, and MCP ensures agentic AI implementations are transparent and governable, with built-in auditability, versioning, and the ability to swap AI models and tools on the fly. Camunda also received above-average customer feedback in Forrester's evaluation, with the report noting that customers praise its effective orchestration. In summary, Forrester says, 'Camunda best suits enterprises with professional developers who want to automate complex processes and require best-in-class orchestration.' Additional information The Forrester DPA Wave report is available here. More information about Camunda in the 2025 Forrester Wave™ DPA report is available on Camunda's blog. For more information about Camunda's agentic orchestration capabilities, visit Join Camunda's webinar AI in the real world - how enterprises orchestrate for outcomes, not just outputs, featuring Forrester on September 9, 2025. About Camunda Camunda enables organizations to orchestrate and automate processes across people, systems, and devices to continuously overcome complexity, increase efficiency, and fully operationalize AI. Built for business and IT, Camunda's leading orchestration and automation platform executes any process at the required speed and scale to remain competitive without compromising security, governance, or innovation. Over 700 companies across all industries, including Atlassian, ING, and Vodafone, trust Camunda with the design, orchestration, automation, and improvement of their business-critical processes to accelerate digital transformation. To learn more, visit here.
Business Wire
31 minutes ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
